2024 Policy Preview: An Interview with Dr. Mark McClellan

Scott and Mark welcome Dr. Mark McClellan, a distinguished health policy expert who has served as the Commissioner of the FDA and the Administrator of CMS, to look ahead at the major policy activities in 2024. They discuss how the government's role as regulator and purchaser of drugs will influence the drug industry and the patient's ability to access and afford medicines this year. They also discuss the challenges and opportunities for improving public health and the emerging role of artificial intelligence. Dr. Mark McClellan, PhD, Director and Professor of Business, Medicine and Policy at the Duke-Margolis Center for Health Policy at Duke University IRA Medicare Part D Pharmacy Benefit Managers (PBMs) Medicare Advantage FDA commissioner Rob Califf  The Ryan White HIV/AIDS Program (RWHAP) Part B Medicare Modernization Act FDA FDA's Office of Regulatory Affairs Centers for Medicare & Medicaid Services (CMS)  Centers for Disease Control and Prevention (CDC) Per Member Per Month (PMPM) billing  Questions or comments?Email us at [email protected] us on social media! Follow us on X, LinkedIn, YouTube and Threads.